Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden heart and kidney disease: 16,660 people screened in major spanish study

NCT ID NCT03228459

Knowledge-focused Sponsor: Institut de Recerca Biomèdica de Lleida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study screened over 16,600 adults aged 45-70 with at least one risk factor (like high blood pressure or smoking) but no known heart disease. Researchers used ultrasound and simple blood and urine tests to find hidden signs of atherosclerosis, pre-diabetes, and kidney disease. The goal is to learn what factors contribute to these hidden conditions and whether early detection can reduce future heart attacks and deaths.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify hidden risk factors for heart and kidney disease in seemingly healthy people, leading to better prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change patient outcomes, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16,660 people

The number who actually took part.

Started

Jan 2015

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * women (50-70 years) and men ( 45-65 years) with at least one cardiovascular risk factor (hypertension, dyslipidemia, obesity (BMI \>30 Kg/m2), current smoking habit or former smoker (\<10 years), first-degree family history of early cardiovascular disease). Exclusion Criteria: * Prior medical history of cardiovascular disease. * Diabetes. * Glomerular filtration rate (CKD-EPI \< 60 ml/min/1.73m2). * Active neoplasm or acute disease. * A life expectancy \< 18 months. * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome atherosclerosis atrial fibrillation chronic kidney disease chronic renal failure syndrome diabetes mellitus disease kidney disorder metabolic syndrome X prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Chronic kidney diseases Metabolic syndrome Prediabetes Subclinical disease and/or syndrome

Contacts and locations

Locations

  • Fundació Renal Jaume Arnò

    Lleida, Lleida, 25006, Spain

  • Institut de recerca Biomèdica de Lleida

    Lleida, Lleida, 25198, Spain

  • Primary Care centre

    Lleida, Lleida, 25007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.